Ari J. Rosenberg

1.2k total citations
69 papers, 636 citations indexed

About

Ari J. Rosenberg is a scholar working on Oncology, Otorhinolaryngology and Surgery. According to data from OpenAlex, Ari J. Rosenberg has authored 69 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 36 papers in Otorhinolaryngology and 17 papers in Surgery. Recurrent topics in Ari J. Rosenberg's work include Head and Neck Cancer Studies (36 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Lung Cancer Research Studies (8 papers). Ari J. Rosenberg is often cited by papers focused on Head and Neck Cancer Studies (36 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Lung Cancer Research Studies (8 papers). Ari J. Rosenberg collaborates with scholars based in United States, Japan and Israel. Ari J. Rosenberg's co-authors include Mark Agulnik, Everett E. Vokes, Devalingam Mahalingam, Nishant Agrawal, Alexander T. Pearson, Evgeny Izumchenko, Aditya Juloori, Mark W. Lingen, Tanguy Y. Seiwert and Xiangying Chen and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ari J. Rosenberg

60 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ari J. Rosenberg United States	14	336	198	161	160	141	69	636
Adel K. El-Naggar United States	11	296 0.9×	297 1.5×	228 1.4×	229 1.4×	180 1.3×	13	792
Amy Meister United States	7	551 1.6×	206 1.0×	104 0.6×	240 1.5×	125 0.9×	9	674
Nagaaki Terakado Japan	18	420 1.3×	183 0.9×	201 1.2×	149 0.9×	313 2.2×	30	872
Akiyuki Hirosue Japan	17	347 1.0×	176 0.9×	138 0.9×	73 0.5×	356 2.5×	42	822
Wendong Gu China	18	243 0.7×	67 0.3×	192 1.2×	255 1.6×	283 2.0×	56	784
Akimitsu Hiraki Japan	12	251 0.7×	94 0.5×	99 0.6×	62 0.4×	181 1.3×	21	528
Yong Bao China	16	316 0.9×	178 0.9×	223 1.4×	318 2.0×	245 1.7×	60	780
Willa Shi Canada	7	238 0.7×	237 1.2×	138 0.9×	113 0.7×	200 1.4×	7	563
Françoise Drusch France	14	544 1.6×	133 0.7×	114 0.7×	195 1.2×	215 1.5×	17	924
Minghuan Li China	17	368 1.1×	45 0.2×	280 1.7×	494 3.1×	117 0.8×	46	912

Countries citing papers authored by Ari J. Rosenberg

Since Specialization

Citations

This map shows the geographic impact of Ari J. Rosenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ari J. Rosenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ari J. Rosenberg more than expected).

Fields of papers citing papers by Ari J. Rosenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ari J. Rosenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ari J. Rosenberg. The network helps show where Ari J. Rosenberg may publish in the future.

Co-authorship network of co-authors of Ari J. Rosenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Ari J. Rosenberg. A scholar is included among the top collaborators of Ari J. Rosenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ari J. Rosenberg. Ari J. Rosenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenberg, Ari J., Evgeny Izumchenko, Aditya Juloori, et al.. (2025). Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer. Clinical Cancer Research. 31(15). 3150–3159. 1 indexed citations

Bossi, Paolo, Naomi Kiyota, Ricard Mesı́a, et al.. (2025). Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review. Oral Oncology. 169. 107596–107596. 1 indexed citations

Luan, Jingyun, Xuejie Huang, Benjamin Nicholson, et al.. (2025). Tumor-initiating stem cells fine-tune the plasticity of neutrophils to sculpt a protective niche. Cancer Cell. 44(1). 94–111.e11.

Jagadeeshan, Sankar, Manu Prasad, Noam Erez, et al.. (2025). Anti-PD1 prolongs the response of PI3K and farnesyl transferase inhibition in HRAS- and PIK3CA-mutant head and neck cancers. Neoplasia. 63. 101157–101157. 1 indexed citations

Izumchenko, Evgeny, Claudia Wing, Xiangying Cheng, et al.. (2024). Saliva-based detection of oral HPV and oral cancer.. Journal of Clinical Oncology. 42(16_suppl). 6057–6057. 2 indexed citations

Rosenberg, Ari J., et al.. (2024). Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. American Society of Clinical Oncology Educational Book. 44(3). e433330–e433330. 5 indexed citations

Shen, Colette J., Jessica M. Frakes, Trevor Hackman, et al.. (2024). Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.. Journal of Clinical Oncology. 42(16_suppl). 6035–6035. 3 indexed citations

Rosenberg, Ari J., Aditya Juloori, Evgeny Izumchenko, et al.. (2024). Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV.. Journal of Clinical Oncology. 42(16_suppl). 6017–6017. 4 indexed citations

Swiecicki, Paul, Emrullah Yilmaz, Ari J. Rosenberg, et al.. (2024). Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. Journal of Clinical Oncology. 43(5). 578–588. 9 indexed citations

10.

Swiecicki, Paul, Emrullah Yilmaz, Ari J. Rosenberg, et al.. (2024). Enfortumab Vedotin (EV) in the Previously Treated Advanced Head and Neck Cancer (HNC) Cohort of EV-202. International Journal of Radiation Oncology*Biology*Physics. 118(5). e18–e18. 1 indexed citations

11.

Pearson, Alexander T., Tanguy Y. Seiwert, Roger B. Cohen, et al.. (2024). A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.. Journal of Clinical Oncology. 42(16_suppl). 6008–6008. 4 indexed citations

12.

Rosenberg, Ari J., Evgeny Izumchenko, Aditya Juloori, et al.. (2023). 886P Prospective evaluation of dynamic changes of cell-free HPV-DNA (cfHPV-DNA) in locoregional HPV associated (HPV+) oropharyngeal cancer (OPC) treated with neoadjuvant chemotherapy and response-stratified treatment. Annals of Oncology. 34. S568–S568.

13.

Nabell, Lisle M., Alan L. Ho, Marshall R. Posner, et al.. (2023). 921P HB-200 arenavirus-based immunotherapy plus pembrolizumab as a first-line treatment of patients with recurrent/metastatic HPV16 positive head and neck cancer. Annals of Oncology. 34. S581–S582. 3 indexed citations

14.

Rosenberg, Ari J., Theodore Karrison, Jonas A. de Souza, et al.. (2023). A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Annals of Oncology. 34(8). 714–722. 2 indexed citations

15.

Huang, Dandan, Ari J. Rosenberg, Nishant Agrawal, et al.. (2023). Long-Term Results of Induction Chemotherapy Followed by 50 Gy Radiation Therapy Alone for Low-Risk HPV-Positive Oropharynx Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). S151–S152. 1 indexed citations

16.

Singh, Alka, Xiangying Chen, Claudia Wing, et al.. (2023). Abstract 4897: PRT543, a methyl transferase inhibitor, has potent anti-tumor activity against adenoid cystic carcinoma of salivary glands. Cancer Research. 83(7_Supplement). 4897–4897. 1 indexed citations

17.

Ferrarotto, Renata, Oz Solomon, Rami Rauch, et al.. (2022). AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death and Disease. 13(8). 678–678. 32 indexed citations

18.

Le, Xiuning, Corinne Maurice‐Dror, Aru Panwar, et al.. (2020). 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma. Annals of Oncology. 31. S685–S685. 3 indexed citations

19.

Rosenberg, Ari J. & Mark Agulnik. (2018). Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment. Current Treatment Options in Oncology. 19(4). 19–19. 99 indexed citations

20.

Lanning, Kevin & Ari J. Rosenberg. (2009). The dimensionality of American political attitudes: tensions between equality and freedom in the wake of September 11. Behavioral Sciences of Terrorism and Political Aggression. 1(2). 84–100.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact